Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer. Filed for IPO $HARP httpswww.businesswire.comnewshome20190102005182enHarpoonTherapeuticsAnnouncesPreliminarySafetyPharm

Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer. Filed for #IPO $HARP https://www.businesswire.com/news/home/20190102005182/en/Harpoon-Therapeutics-Announces-Preliminary-Safety-Pharm

08:33 EST 2 Jan 2019 | Odi Bruckman

Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer. Filed for #IPO $HARP https://www.businesswire.com/news/home/20190102005182/en/Harpoon-Therapeutics-Announces-Preliminary-Safety-Pharmacology-Data …

More From BioPortfolio on "Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer. Filed for #IPO $HARP https://www.businesswire.com/news/home/20190102005182/en/Harpoon-Therapeutics-Announces-Preliminary-Safety-Pharm"